| Previous Close | N/A |
| Open | N/A |
| Bid | N/A |
| Ask | N/A |
| Strike | N/A |
| Expire Date | N/A |
| Day's Range | N/A - N/A |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswirePacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across AsiaSINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's advance
- GlobeNewswire
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-f
- GlobeNewswire
PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore
The new lab will leverage PacBio’s HiFi sequencing technology to broaden access to highly accurate long-read sequencing and multi-omics solutions in Southeast AsiaSINGAPORE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the Agency for Science, Technology, and Research (A*STAR), and Macrogen, today announced the opening of a state-of-the-art joint laboratory at A*STAR Genome Institute of Si
